Health Care [ 1/12 ] | Biotechnology [ 8/73 ]
NASDAQ | Common Stock
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions.
The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.
It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device.
Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 6, 25 | -1.31 Increased by +39.91% | -1.39 Increased by +5.76% |
| Aug 11, 25 | -1.87 Increased by +16.89% | -1.26 Decreased by -48.41% |
| May 8, 25 | -2.09 Decreased by -1.99 K% | -2.15 Increased by +2.79% |
| Mar 13, 25 | -2.55 Decreased by -5.00 K% | -0.15 Decreased by -1.60 K% |
| Nov 7, 24 | -2.18 Decreased by -2.64 K% | -0.12 Decreased by -1.72 K% |
| Aug 7, 24 | -2.25 Decreased by -66.67% | -0.12 Decreased by -1.77 K% |
| May 9, 24 | -0.10 Increased by +98.49% | -0.07 Decreased by -42.86% |
| Mar 11, 24 | -0.05 Increased by +94.12% | -0.08 Increased by +37.50% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 0.00 Decreased by N/A% | -2.69 M Decreased by -11.54% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -3.67 M Decreased by -53.25% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -3.85 M Decreased by -131.19% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 2.13 K Decreased by -22.90% | -4.19 M Decreased by -266.00% | Decreased by -196.22 K% Decreased by -374.74% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -2.41 M Decreased by -132.31% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -2.39 M Decreased by -138.58% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -1.66 M Increased by +67.85% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 2.77 K Increased by +N/A% | -1.14 M Increased by +77.16% | Decreased by -41.33 K% - |